135 related articles for article (PubMed ID: 36915220)
1. Nigrosome 1 visibility and its association with nigrostriatal dopaminergic loss in Parkinson's disease.
Kim HK; Kim T; Baek MS; Kim EY; Sung YH; Lee JH; Ryu YH; Ahn SJ; Yoo HS; Lyoo CH
Eur J Neurol; 2023 Jun; 30(6):1639-1647. PubMed ID: 36915220
[TBL] [Abstract][Full Text] [Related]
2. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
3. Determining the Degree of Dopaminergic Denervation Based on the Loss of Nigral Hyperintensity on SMWI in Parkinsonism.
Bae YJ; Song YS; Kim JM; Choi BS; Nam Y; Choi JH; Lee WW; Kim JH
AJNR Am J Neuroradiol; 2021 Apr; 42(4):681-687. PubMed ID: 33509919
[TBL] [Abstract][Full Text] [Related]
4. Precise Evaluation of Striatal Oxidative Stress Corrected for Severity of Dopaminergic Neuronal Degeneration in Patients with Parkinson's Disease: A Study with 62Cu-ATSM PET and 123I-FP-CIT SPECT.
Neishi H; Ikawa M; Okazawa H; Tsujikawa T; Arishima H; Kikuta KI; Yoneda M
Eur Neurol; 2017; 78(3-4):161-168. PubMed ID: 28848099
[TBL] [Abstract][Full Text] [Related]
5. A prospective multi-centre study of susceptibility map-weighted MRI for the diagnosis of neurodegenerative parkinsonism.
Sung YH; Kim JS; Yoo SW; Shin NY; Nam Y; Ahn TB; Yoo D; Lee KM; Kim HG; Koh SB; Kim J; Kim I; Kwon DY; Lee Y; Kim C; Chung SJ; Jo S; Lee SH; Kim SJ; Kim M; Lyoo CH; Baek MS; Kang SY; Chang SK; Jo SW; Lee SA; Ma HI; Kim YE; Kim ES; Kim YJ; Kim HS; Woo MH; Choi HJ; Kim EY
Eur Radiol; 2022 May; 32(5):3597-3608. PubMed ID: 35064313
[TBL] [Abstract][Full Text] [Related]
6. Imaging of nigrosome 1 in substantia nigra at 3T using multiecho susceptibility map-weighted imaging (SMWI).
Nam Y; Gho SM; Kim DH; Kim EY; Lee J
J Magn Reson Imaging; 2017 Aug; 46(2):528-536. PubMed ID: 27859983
[TBL] [Abstract][Full Text] [Related]
7. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.
Iranzo A; Valldeoriola F; Lomeña F; Molinuevo JL; Serradell M; Salamero M; Cot A; Ros D; Pavía J; Santamaria J; Tolosa E
Lancet Neurol; 2011 Sep; 10(9):797-805. PubMed ID: 21802993
[TBL] [Abstract][Full Text] [Related]
8. Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson's disease.
Lee SH; Lee MJ; Lyoo CH; Cho H; Lee MS
J Neural Transm (Vienna); 2018 Sep; 125(9):1333-1339. PubMed ID: 29971496
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal Change of DAT SPECT in Parkinson's Disease and Multiple System Atrophy.
Sakakibara S; Hashimoto R; Katayama T; Kenjyo M; Yokokawa Y; Saito Y; Hirakawa A; Ito M; Nakamura T; Hara K; Hashizume A; Aiba I; Inukai A; Katsuno M
J Parkinsons Dis; 2020; 10(1):123-130. PubMed ID: 31707374
[TBL] [Abstract][Full Text] [Related]
10. Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease.
Happe S; Baier PC; Helmschmied K; Meller J; Tatsch K; Paulus W
J Neurol; 2007 Aug; 254(8):1037-43. PubMed ID: 17351722
[TBL] [Abstract][Full Text] [Related]
11. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions.
Park SB; Kwon KY; Lee JY; Im K; Sunwoo JS; Lee KB; Roh H; Ahn MY; Park S; Kim SJ; Oh JS; Kim JS
Neurol Sci; 2019 Feb; 40(2):311-317. PubMed ID: 30415448
[TBL] [Abstract][Full Text] [Related]
12. The effect of dopamine on response inhibition in Parkinson's disease relates to age-dependent patterns of nigrostriatal degeneration.
Kübler D; Schroll H; Hamker FH; Joutsa J; Buchert R; Kühn AA
Parkinsonism Relat Disord; 2019 Jun; 63():185-190. PubMed ID: 30765262
[TBL] [Abstract][Full Text] [Related]
13. Nigrostriatal dopamine transporter availability in early Parkinson's disease.
Fazio P; Svenningsson P; Cselényi Z; Halldin C; Farde L; Varrone A
Mov Disord; 2018 Apr; 33(4):592-599. PubMed ID: 29436751
[TBL] [Abstract][Full Text] [Related]
14. Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease.
Caminiti SP; Presotto L; Baroncini D; Garibotto V; Moresco RM; Gianolli L; Volonté MA; Antonini A; Perani D
Neuroimage Clin; 2017; 14():734-740. PubMed ID: 28409113
[TBL] [Abstract][Full Text] [Related]
15. Automated assessment of the substantia nigra on susceptibility map-weighted imaging using deep convolutional neural networks for diagnosis of Idiopathic Parkinson's disease.
Shin DH; Heo H; Song S; Shin NY; Nam Y; Yoo SW; Kim JS; Yoon JH; Lee SH; Sung YH; Kim EY
Parkinsonism Relat Disord; 2021 Apr; 85():84-90. PubMed ID: 33761389
[TBL] [Abstract][Full Text] [Related]
16. Quantitative [(123)I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson's disease.
Alvarez-Fischer D; Blessmann G; Trosowski C; Béhé M; Schurrat T; Hartmann A; Behr TM; Oertel WH; Höglinger GU; Höffken H
Neuroimage; 2007 Oct; 38(1):5-12. PubMed ID: 17716921
[TBL] [Abstract][Full Text] [Related]
17. Initial diagnostic workup of parkinsonism: Dopamine transporter positron emission tomography versus susceptibility map-weighted imaging at 3T.
Sung YH; Lee J; Nam Y; Shin HG; Noh Y; Hwang KH; Lee H; Kim EY
Parkinsonism Relat Disord; 2019 May; 62():171-178. PubMed ID: 30580909
[TBL] [Abstract][Full Text] [Related]
18. A preliminary attempt to visualize nigrosome 1 in the substantia nigra for Parkinson's disease at 3T: An efficient susceptibility map-weighted imaging (SMWI) with quantitative susceptibility mapping using deep neural network (QSMnet).
Jo M; Oh SH
Med Phys; 2020 Mar; 47(3):1151-1160. PubMed ID: 31883389
[TBL] [Abstract][Full Text] [Related]
19. An FP-CIT PET comparison of the difference in dopaminergic neuronal loss in subtypes of early Parkinson's disease.
Song IU; Chung YA; Oh JK; Chung SW
Acta Radiol; 2014 Apr; 55(3):366-71. PubMed ID: 23943629
[TBL] [Abstract][Full Text] [Related]
20. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.
Sakakibara R; Shinotoh H; Uchiyama T; Yoshiyama M; Hattori T; Yamanishi T
J Neurol Sci; 2001 Jun; 187(1-2):55-9. PubMed ID: 11440745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
